OncoMatch/Clinical Trials/NCT05990465
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Is NCT05990465 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Pirtobrutinib and LV20.19 CAR T cells for non hodgkin lymphoma.
Treatment: Pirtobrutinib · LV20.19 CAR T cells — This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Prior therapy
Must have received: anti-CD20 antibody (rituximab) — with chemotherapy regimen appropriate for disease
Must have received Rituximab or another cluster of differentiation 20 (CD20) antibody with combination anthracycline based chemotherapy regimen
Cannot have received: anti-CD20 antibody
Anti-CD20 antibody treatment within 4 weeks of cell infusion
Cannot have received: anti-CD19 antibody
Anti-CD19 antibody treatment within 4 weeks of cell infusion
Cannot have received: cytotoxic chemotherapy
Cytotoxic chemotherapy treatment within 14 days ... prior to apheresis collection for CAR-T cells
Lab requirements
Blood counts
ANC ≥1000/μL (no G-CSF within 7 days or pegylated G-CSF within 14 days unless bone marrow involvement); Platelets ≥50,000/μL (no transfusion within 7 days unless bone marrow involvement); Hemoglobin ≥8g/dL (transfusions allowed)
Kidney function
creatinine clearance ≥50 ml/min (apheresis/CAR-T/pirtobrutinib start); ≥40 ml/min (pirtobrutinib maintenance)
Liver function
AST and ALT <3 x ULN; serum bilirubin and alkaline phosphatase <3 x ULN, or considered not clinically significant as per the clinical PI's discretion (e.g., Gilbert's or indirect hyperbilirubinemia) or felt to be due to underlying disease.
Cardiac function
NYHA I or II AND LVEF ≥45% (by ECHO or MUGA); room air oxygen saturation ≥92%
See organ function criteria for pirtobrutinib bridging, maintenance, and apheresis/CAR-T cells.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify